cPass(TM) SARS-CoV-2 Neutralization Antibody kit is the first EUA authorized test that detects neutralizing antibodies within one hour

Food and Healthcare Press Releases Wednesday November 11, 2020 15:20
SINGAPORE--11 Nov--PRNewswire/InfoQuest

Following GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK)'s cPass(TM) SARS-CoV-2 Neutralization Antibody Detection Kit has received provisional authorization by Health Science Authority (HSA) Singapore on 8th May 2020, CE-IVD marking in Europe on 26th May 2020 and FDA approval in Philippines for commercial use on 11th August 2020.

U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for cPass(TM) SARS-CoV-2 Neutralization Antibody Detection Kit on 6th November 2020.

cPass(TM) SARS-CoV-2 Neutralization Antibody Detection Kit which is co- developed with Duke-NUS Medical School Singapore and Diagnostics Development Hub from Singapore's Agency for Science, Technology and Research (A*STAR) and manufactured by GenScript Biotech Corporation, is the first serology test authorized to detect neutralizing antibodies - the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection, without the need of live biological materials and biocontainment facility. The test measures the presence of neutralizing antibodies in patients recovering from COVID-19 or receiving a vaccine.

GenScript has started to serve global market through authorized distributors and authorized laboratories to provide the test to public. GenScript promised to support the healthcare community and continue the fight against COVID-19.

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform and the industrial synthesis product platform.

GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript's business operation spans over 100 countries and regions worldwide, with legal entities located in the U.S., Mainland China, Hong Kong, Japan, Singapore, Netherlands and Ireland. GenScript has provided premium, convenient, and reliable products and services for over 100,000 customers.

GenScript has a number of intellectual property rights and technical secrets, including more than 100 patents and over 270 patent applications. As of June 30, 2020, GenScript's products and services have been cited by 51,000 peer-reviewed journal articles worldwide.


Latest Press Release

MIM Software Inc. ประกาศความร่วมมือกับ Peter MacCallum Cancer Centre เพื่อปรับปรุงการจัดการผู้ป่วย

MIM Software Inc. บริษัทชั้นนำระดับโลกผู้ให้บริการซอฟต์แวร์การถ่ายภาพทางการแพทย์ ประกาศความร่วมมือกับโรงพยาบาล Peter MacCallum Cancer Centre (Peter Mac) ผ่านทางโปรแกรม Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) Peter Mac และ...

Thailand EEPO 2020: The road to digitalize the Thai public healthcare system

The public healthcare system in Thailand had witnessed many meaningful advancements, thanks to the improvement of technologies and medical innovations. This vast improvement owed a great deal to the cooperation between various stakeholders, who have...

MIM Software Inc. Announces Collaboration with Peter MacCallum Cancer Centre to Improve Patient Management

MIM Software Inc., a leading global provider of medical imaging software, announced today a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in support of its Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC)...

Global leaders welcome the Sanitation and Hygiene Fund as key to increasing investment

The Sanitation and Hygiene Fund will be critical to dramatically scale up investments to reach everyone with sanitation services, United Nations Deputy Secretary-General has said as the new financial mechanism to drive billions of dollars into the...

Takara Belmont Discovers Changes at Core of Hair Structure; Resulting "Hair Medulla Care" Technology Will Change Future of Haircare

Takara Belmont Corporation (hereinafter Takara Belmont) has developed a new technology for analyzing hair, leading to the discovery of structural changes in the medulla, the central part of hair previously largely not visible to researchers. As a result,...

Related Topics